ストックスクリーナーアプリを入手
1.41
6.00%
-0.09
前日終値:
$1.50
開ける：
$1.5
24時間の取引高:
38,031
Relative Volume:
2.88
時価総額：
$60.97M
収益：
$1.88M
当期純損益:
$-15.57M
株価収益率:
-3.525
EPS:
-0.4
ネットキャッシュフロー:
$-50.09M
1週間 パフォーマンス:
-2.08%
1か月 パフォーマンス:
-17.06%
6か月 パフォーマンス:
-40.51%
1年 パフォーマンス:
-45.77%
1日の値動き範囲:
$1.40
$1.66
1週間の範囲:
$1.37
$1.66
52週間の値動き範囲:
$1.37
$3.625
Beyondspring Inc Stock (BYSI) Company Profile
名前
Beyondspring Inc
セクター
電話
646-528-4184
住所
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
BYSI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
1.40 | 60.97M | 1.88M | -15.57M | -50.09M | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.83 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.18 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.52 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.96 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
239.91 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-02 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-12-02 | ダウングレード | Jefferies | Buy → Hold |
| 2021-12-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | 開始されました | Robert W. Baird | Outperform |
| 2021-08-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | 開始されました | BofA Securities | Buy |
| 2020-12-29 | 開始されました | Evercore ISI | Outperform |
| 2020-02-07 | 開始されました | Jefferies | Buy |
| 2020-01-10 | 開始されました | Nomura | Buy |
| 2019-12-03 | 開始されました | William Blair | Outperform |
| 2019-07-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-04-30 | ダウングレード | Maxim Group | Buy → Hold |
| 2018-10-25 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Beyondspring Inc (BYSI) 最新ニュース
BeyondSpring (NASDAQ:BYSI) Trading Down 3.8%Here's Why - MarketBeat
BeyondSpring’s 2024 Progress and Strategic Milestones - TipRanks
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline By Investing.com - Investing.com South Africa
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline - Investing.com
BeyondSpring Inc. (BYSI) reports earnings - Quartz
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones - The Manila Times
BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewswire
Just Released: BeyondSpring's Complete 2024 Financial Performance and Cancer Pipeline Updates - Stock Titan
Global Febrile Neutropenia Market Forecast 2025-2034: Analyzing Growth Drivers, Market Share, Segments, And - EIN News
In-Depth Analysis Of The Global Febrile Neutropenia Market Advancements Highlighted by Key Drivers, Trends,... - WhaTech
BeyondSpring's PlinabulinA Pipeline In Itself? - RTTNews
Molecular Glues Market to Register Stunning Growth During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve
BeyondSpring, Inc. to Host Earnings Call - ACCESS Newswire
Pliant Therapeutics stock tumbles amid IPF trial cancellation - Clinical Trials Arena
BeyondSpring finalizes significant asset sale By Investing.com - Investing.com South Africa
BeyondSpring finalizes significant asset sale - Investing.com India
BeyondSpring (NASDAQ:BYSI) Stock Price Up 0.6%Time to Buy? - MarketBeat
Cancer Vaccines Market on Track for Major Expansion in - One News Page
Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - Citeline News & Insights
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 - MSN
BeyondSpring Inc. Enters into Preferred Share Purchase Agreement with SEED Therapeutics Inc. - Defense World
BeyondSpring sells SEED Therapeutics shares for $35.4M - MSN
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors - The Manila Times
BeyondSpring sells SEED Therapeutics shares for $35.4M By Investing.com - Investing.com UK
BeyondSpring Announces $35.4 Million Sale of a Portion of - GlobeNewswire
SEED Receives FDA Rare Pediatric Disease and Orphan Drug - GlobeNewswire
BeyondSpring Cashes In $35M Stake as Cancer Drug Shows 89% Disease Control Rate - StockTitan
BeyondSpring (NASDAQ:BYSI) Shares Down 1.4%Here's Why - MarketBeat
Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight - The Malaysian Reserve
BeyondSpring Inc. Announces Change in Domestic Filing Status and Disclosure Channels to Disseminate Information - Defense World
BeyondSpring (BYSI) Stock Drops Amidst Biotech Sector Volatility - GuruFocus.com
Germ Cell Tumors Market to Register Significant Growth at a CAGR of 5.5% by 2034 | DelveInsight - The Malaysian Reserve
CTLA-4 Inhibitors Market to Advance at Moderate CAGR During the Study Period (2020-2034) | DelveInsight - The Malaysian Reserve
Retail investors reap multibagger gains by betting on these 29 - Oficjalny Portal Gminy Brzesko
BeyondSpring (NASDAQ:BYSI) Shares Up 4.5%Here's Why - MarketBeat
BeyondSpring (NASDAQ:BYSI) Trading 4.5% Higher – Here’s Why - Defense World
Non-small Cell Lung Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail
Non-small Cell Lung Cancer Treatment Market 2032: Clinical - openPR
Beyondspring Inc (BYSI) 財務データ
収益
当期純利益
現金流量
EPS
2.65%
0.06%
大文字化:
|
ボリューム (24 時間):